Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials

AIMS: To assess the therapeutic potential of fatty acid synthase (FASN) inhibition with FT‐4101, a potent, selective, orally bioavailable, small‐molecule by (a) evaluating the dose−response of single FT‐4101 doses (3, 6 and 9 mg) on hepatic de novo lipogenesis (DNL) in healthy participants (Study 1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Beysen, Carine, Schroeder, Patricia, Wu, Eric, Brevard, Julie, Ribadeneira, Maria, Lu, Wei, Dole, Kiran, O'Reilly, Terry, Morrow, Linda, Hompesch, Marcus, Hellerstein, Marc K., Li, Kelvin, Johansson, Lars, Kelly, Patrick F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898808/
https://www.ncbi.nlm.nih.gov/pubmed/33289350
http://dx.doi.org/10.1111/dom.14272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898808/
https://www.ncbi.nlm.nih.gov/pubmed/33289350
http://dx.doi.org/10.1111/dom.14272

Ejemplares similares